Lee Jee-Soo, Gu JaYoon, Yoo Hyun Ju, Koh Youngil, Kim Hyun Kyung
Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea.
Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Anyang, Seoul, Korea.
Ann Clin Lab Sci. 2017 May;47(3):319-322.
We report a novel gene mutation c.1315A>G (p.Lys439Glu) identified in a family, which caused evidently different hematologic phenotypes. The proband was a 17-year-old man with severe microcytic hypochromic anemia, excessive ring sideroblasts in the bone marrow, and iron overload. A hemizygous mutation in exon 9, c.1315A>G (p.Lys439Glu), was identified through sequence analysis. We assume that this amino acid substitution affects the enzymatic activity of ALAS2 by affecting its interaction with the cofactor pyridoxal 5'-phosphate, since the patient was responsive to pyridoxine treatment. This novel mutation likely accounts for variable hematologic phenotypes in the family of this patient: his 15-year-old hemizygous brother was asymptomatic, while his heterozygous mother was mildly anemic.
我们报告了在一个家族中鉴定出的一种新的基因突变c.1315A>G(p.Lys439Glu),该突变导致了明显不同的血液学表型。先证者是一名17岁男性,患有严重的小细胞低色素性贫血、骨髓中过多的环形铁粒幼细胞以及铁过载。通过序列分析鉴定出第9外显子中的半合子突变c.1315A>G(p.Lys439Glu)。由于患者对吡哆醇治疗有反应,我们推测这种氨基酸替代通过影响其与辅因子磷酸吡哆醛的相互作用来影响ALAS2的酶活性。这种新的突变可能解释了该患者家族中可变的血液学表型:他15岁的半合子弟弟无症状,而他的杂合子母亲有轻度贫血。